{"id":44056,"date":"2022-05-18T13:01:29","date_gmt":"2022-05-18T11:01:29","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\/"},"modified":"2022-05-18T13:01:29","modified_gmt":"2022-05-18T11:01:29","slug":"epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\/","title":{"rendered":"EpiEndo: Successful Completion of Phase I Study for Lead Asset EP395"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<i>First non-antibiotic macrolide to go into clinical development \u2013 targeting COPD<\/i>\n<\/li>\n<li>\n<i>Safety, tolerability and pharmacokinetic endpoints met<\/i>\n<\/li>\n<li>\n<i>Phase II planning underway<\/i>\n<\/li>\n<\/ul>\n<p>REYKJAVIK, Iceland&#8211;(BUSINESS WIRE)&#8211;<b>EpiEndo Pharmaceuticals <\/b>(\u2018EpiEndo\u2019), the clinical-stage biopharmaceutical company developing disease-modifying therapeutics for chronic respiratory disorders, has completed its Phase I First Time in Human (FTIH) study with EP395 in healthy subjects.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220518005094\/en\/1458461\/4\/EpiEndo-Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220518005094\/en\/1458461\/21\/EpiEndo-Logo.jpg\"><\/a><\/p>\n<p>\nEP395, is the first of EpiEndo\u2019s orally available, non-antibiotic macrolides or \u2018Barriolides\u2122\u2019, to enter clinical development and will be targeting chronic obstructive pulmonary disease (COPD). EpiEndo is taking a novel approach to drug development for chronic respiratory diseases, focusing on enhancing the integrity of the epithelial cell layer in the lung to reduce disease-causing inflammation.\n<\/p>\n<p>\nThe study\u2019s Principal Investigator was Professor Dave Singh, professor of clinical pharmacology and respiratory medicine at the University of Manchester. It was designed to assess the safety and tolerability of ascending single and multiple (up to 28 days) doses of the Barriolide\u2122 EP395, administered as oral capsules in healthy subjects. EP395 was well tolerated and with pharmacokinetics consistent with once daily dosing. For more information on the study, see <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2Fstudy%2FNCT04819854&amp;esheet=52722212&amp;newsitemid=20220518005094&amp;lan=en-US&amp;anchor=ClinicalTrials.gov&amp;index=1&amp;md5=b208de9d4d88b27aca411ac50bc4ca75\" rel=\"nofollow noopener\" shape=\"rect\">ClinicalTrials.gov<\/a>.\n<\/p>\n<p>\nCommenting on the study results, <b>EpiEndo\u2019s Chief Medical Officer, Ginny Norris,<\/b> said:\n<\/p>\n<p>\n<i>\u201cThe successful completion of this study brings us a step closer to addressing the global burden of COPD and other airway diseases by restoring and preserving epithelial integrity and reducing inflammation without the issue of potential anti-microbial resistance. We are now planning the next stage of clinical development for EP395 and look forward to initiating 2 clinical studies later this year including the first study with EP395 in COPD patients.\u201d<\/i>\n<\/p>\n<p>\n<b>Principal Investigator, Prof Dave Singh,<\/b> added:\n<\/p>\n<p>\n<i>\u201cThis First Time in Human study provides key clinical insights which highlight the potential for this new class of therapeutic \u2013 an encouraging step towards a new treatment for COPD.\u201d<\/i>\n<\/p>\n<p>\nEpiEndo will begin Phase Ib and Phase IIa studies with EP395 later this year, with top-level data to become available during 2023. The Phase Ib study will be a proof of pharmacology study in healthy volunteers. The Phase IIa study will assess the safety and tolerability of EP395 in patients with COPD, as well as assessing biomarkers for anti-inflammatory efficacy.\n<\/p>\n<p class=\"bwalignc\">\n###\n<\/p>\n<p>\n<b>About EpiEndo Pharmaceuticals (<span class=\"bwuline\"><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.epiendo.com&amp;esheet=52722212&amp;newsitemid=20220518005094&amp;lan=en-US&amp;anchor=www.epiendo.com&amp;index=2&amp;md5=0da59acd6f549df4abe044977c74f049\" rel=\"nofollow noopener\" shape=\"rect\">www.epiendo.com<\/a><\/span>)<\/b>\n<\/p>\n<p>\nEpiEndo is a clinical-stage biopharmaceutical company with a unique approach to inflammatory disorders that focuses on enhancement of epithelial barrier integrity as a critical pathophysiological factor underlying the etiology of a number of major diseases. Epithelial cells are a key component of the barrier that makes up human lung tissue and other organs such as the gut and skin. Compromised integrity of this barrier is implicated in the progression and non-resolution of several chronic inflammatory diseases.\n<\/p>\n<p>\nEpiEndo is developing a proprietary portfolio of non-antibiotic macrolide drugs called Barriolides, with promise as first-in-class disease-modifying therapeutics, to address the huge global burden of chronic diseases of the lung and other organs where there is significant unmet medical need. EpiEndo\u2019s lead drug candidate, EP395, aims to be the first on-market oral, non-antibiotic, barrier strengthening and anti-inflammatory macrolide for the treatment of COPD.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>EpiEndo Pharmaceuticals:<\/b><br \/>Maria Bech, CEO<br \/>\n<br \/>Email: <a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#116;&#111;&#x3a;&#x6d;&#97;r&#x69;&#97;&#46;&#x62;&#x65;&#99;h&#x40;&#101;p&#x69;&#x65;&#110;d&#x6f;&#46;c&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x6d;a&#x72;&#105;a&#x2e;&#98;&#x65;&#x63;h&#x40;&#101;p&#x69;&#101;&#x6e;&#100;o&#x2e;&#99;o&#x6d;<\/a><br \/>Tel: +354 454 0090<\/p>\n<p><b>Instinctif Partners<\/b> (media relations):<br \/>\n<br \/>Rozi Morris \/ Katie Duffell<br \/>\n<br \/>Email: <a target=\"_blank\" href=\"&#109;&#x61;&#x69;l&#116;&#x6f;:&#101;&#x70;&#x69;e&#110;&#x64;o&#64;&#x69;&#x6e;s&#116;&#x69;n&#99;&#x74;&#x69;&#102;&#46;&#x63;o&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x65;&#x70;&#x69;&#x65;&#x6e;&#x64;&#x6f;&#x40;&#x69;&#x6e;&#x73;&#x74;&#x69;&#x6e;&#99;&#116;&#105;&#102;&#46;&#99;&#111;&#109;<\/a><br \/>Tel: +44 20 7457 2020\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>First non-antibiotic macrolide to go into clinical development \u2013 targeting COPD Safety, tolerability and pharmacokinetic endpoints met Phase II planning underway REYKJAVIK, Iceland&#8211;(BUSINESS WIRE)&#8211;EpiEndo Pharmaceuticals (\u2018EpiEndo\u2019), the clinical-stage biopharmaceutical company developing disease-modifying therapeutics for chronic respiratory disorders, has completed its Phase I First Time in Human (FTIH) study with EP395 in healthy subjects. EP395, is &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44056","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>EpiEndo: Successful Completion of Phase I Study for Lead Asset EP395 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EpiEndo: Successful Completion of Phase I Study for Lead Asset EP395 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"First non-antibiotic macrolide to go into clinical development \u2013 targeting COPD Safety, tolerability and pharmacokinetic endpoints met Phase II planning underway REYKJAVIK, Iceland&#8211;(BUSINESS WIRE)&#8211;EpiEndo Pharmaceuticals (\u2018EpiEndo\u2019), the clinical-stage biopharmaceutical company developing disease-modifying therapeutics for chronic respiratory disorders, has completed its Phase I First Time in Human (FTIH) study with EP395 in healthy subjects. EP395, is ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-18T11:01:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220518005094\/en\/1458461\/21\/EpiEndo-Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"EpiEndo: Successful Completion of Phase I Study for Lead Asset EP395\",\"datePublished\":\"2022-05-18T11:01:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\\\/\"},\"wordCount\":539,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220518005094\\\/en\\\/1458461\\\/21\\\/EpiEndo-Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\\\/\",\"name\":\"EpiEndo: Successful Completion of Phase I Study for Lead Asset EP395 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220518005094\\\/en\\\/1458461\\\/21\\\/EpiEndo-Logo.jpg\",\"datePublished\":\"2022-05-18T11:01:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220518005094\\\/en\\\/1458461\\\/21\\\/EpiEndo-Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220518005094\\\/en\\\/1458461\\\/21\\\/EpiEndo-Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EpiEndo: Successful Completion of Phase I Study for Lead Asset EP395\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EpiEndo: Successful Completion of Phase I Study for Lead Asset EP395 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\/","og_locale":"en_US","og_type":"article","og_title":"EpiEndo: Successful Completion of Phase I Study for Lead Asset EP395 - Pharma Trend","og_description":"First non-antibiotic macrolide to go into clinical development \u2013 targeting COPD Safety, tolerability and pharmacokinetic endpoints met Phase II planning underway REYKJAVIK, Iceland&#8211;(BUSINESS WIRE)&#8211;EpiEndo Pharmaceuticals (\u2018EpiEndo\u2019), the clinical-stage biopharmaceutical company developing disease-modifying therapeutics for chronic respiratory disorders, has completed its Phase I First Time in Human (FTIH) study with EP395 in healthy subjects. EP395, is ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\/","og_site_name":"Pharma Trend","article_published_time":"2022-05-18T11:01:29+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220518005094\/en\/1458461\/21\/EpiEndo-Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"EpiEndo: Successful Completion of Phase I Study for Lead Asset EP395","datePublished":"2022-05-18T11:01:29+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\/"},"wordCount":539,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220518005094\/en\/1458461\/21\/EpiEndo-Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\/","url":"https:\/\/pharma-trend.com\/en\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\/","name":"EpiEndo: Successful Completion of Phase I Study for Lead Asset EP395 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220518005094\/en\/1458461\/21\/EpiEndo-Logo.jpg","datePublished":"2022-05-18T11:01:29+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220518005094\/en\/1458461\/21\/EpiEndo-Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220518005094\/en\/1458461\/21\/EpiEndo-Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/epiendo-successful-completion-of-phase-i-study-for-lead-asset-ep395\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"EpiEndo: Successful Completion of Phase I Study for Lead Asset EP395"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44056","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44056"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44056\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44056"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44056"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44056"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}